ALBALON ® (naphazoline hydrochloride ophthalmic solution, USP) 0.1%

Label at a glance#

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Sterile

DESCRIPTION

DESCRIPTION SECTION

Naphazoline hydrochloride, an ocular vasoconstrictor, is an imidazoline derivative sympathomimetic amine. It occurs as a white, odorless crystalline powder having a bitter taste and is freely soluble in water and in alcohol. The active ingredient is represented by the structural formula:

Chemical Name:

SPL UNCLASSIFIED SECTION

2-(1-Naphthylmethyl)-2-imidazoline monohydrochloride

Contains:

SPL UNCLASSIFIED SECTION

Active: naphazoline HCl 1 mg (0.1%). Preservative: benzalkonium chloride 0.1mg (0.01%).
Inactives: Boric acid; edetate disodium; purified water; sodium chloride; sodium carbonate; and hydrochloric acid may be added to adjust the pH (5.5 to 7.0).

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Naphazoline constricts the vascular system of the conjunctiva. It is presumed that this effect is due to direct stimulation of the drug upon the alpha-adrenergic receptors in the arterioles of the conjunctiva, resulting in decreased conjunctival congestion. Naphazoline belongs to the imidazoline class of sympathomimetics.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Naphazoline Hydrochloride Ophthalmic Solution is indicated for use as a topical ocular vasoconstrictor.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Contraindicated in the presence of an anatomically narrow angle or in narrow-angle glaucoma or in persons who have shown hypersensitivity to any component of this preparation.

WARNINGS

WARNINGS SECTION

Patients under therapy with MAO inhibitors may experience a severe hypertensive crisis if given a sympathomimetic drug. Use in children, especially infants, may result in CNS depression leading to coma and marked reduction in body temperature.

PRECAUTIONS

PRECAUTIONS SECTION

General:

GENERAL PRECAUTIONS SECTION

For topical ophthalmic use only. Use with caution in the presence of hypertension, cardiovascular abnormalities, hyperglycemia (diabetes), hyperthyroidism, infection or injury.

Patient Information:

INFORMATION FOR PATIENTS SECTION

Patients should be advised to discontinue the drug and consult a physician if relief is not obtained within 48 hours of therapy, if irritation, blurring or redness persists or increases, or if symptoms of systemic absorption occur, i.e., dizziness, headache, nausea, decrease in body temperature, or drowsiness.

To prevent contaminating the dropper tip and solution, do not touch the eyelids or the surrounding area with the dropper tip of the bottle. If solution changes color or becomes cloudy, do not use.

Drug Interactions:

DRUG INTERACTIONS SECTION

Concurrent use of maprotiline or tricyclic antidepressants and naphazoline may potentiate the pressor effect of naphazoline. Patients under therapy with MAO inhibitors may experience a severe hypertensive crisis if given a sympathomimetic drug. (See WARNINGS.)

Pregnancy:

PREGNANCY SECTION

SPL UNCLASSIFIED SECTION

Pregnancy Category C: Animal reproduction studies have not been
conducted with naphazoline. It is also not known whether naphazoline can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Naphazoline should be given to a pregnant woman only if clearly needed.

Nursing Mothers:

NURSING MOTHERS SECTION

It is not known whether naphazoline is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when naphazoline is administered to a nursing woman.

Pediatric Use:

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established. See “WARNINGS.” and “CONTRAINDICATIONS.”

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

SPL UNCLASSIFIED SECTION

Ocular: Mydriasis, increased redness, irritation, discomfort, blurring, punctate keratitis, lacrimation, increased intraocular pressure.

SPL UNCLASSIFIED SECTION

Systemic: Dizziness, headache, nausea, sweating , nervousness, drowsiness, weakness, hypertension, cardiac irregularities, and hyperglycemia.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Instill one or two drops in the conjunctival sac(s) every three to four hours as needed.

HOW SUPPLIED

HOW SUPPLIED SECTION

Naphazoline Hydrochloride Ophthalmic Solution, USP) is supplied as a sterile 0.1% solution in

      15 mL plastic dropper bottles. NDC 17478-216-12

Storage: Store at 20° to 25°C (68° to 77°F). Keep container tightly closed.

Rx Only

Manufactured by:

Akorn Inc.
Lake Forest, IL 60045

Repackaged by:

Rebel Distributors Corp

Thousand Oaks, CA 91320

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

AK-Con 0.1%

DailyMed RxNorm Mappings#

DailyMed Product Concepts#

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

DailyMed Dashboard NDC Coverage#

DailyMed Billing Units#

DailyMed Socrata Ingredients#

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

• AK-Con
• naphazoline hydrochloride
• naphazoline
• edetate disodium
• water
• sodium chloride
• SODIUM CARBONATE
• BENZALKONIUM CHLORIDE
• HYDROCHLORIC ACID
• BORIC ACID

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 8 · 428 matching rows.

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.